“The Phase 1 clinical trial is designed to evaluate the safety, reactogenicity, and immunogenicity of ARCT-2304 as a potential vaccine to protect against the highly pathogenic H5N1 avian influenza.” ...
The first presumptive human case of avian bird flu has been found in Canada. Here's what you need to know about avian flu.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback